Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

2008 ◽  
Vol 26 (20) ◽  
pp. 3403-3410 ◽  
Author(s):  
Matthew H. Kulke ◽  
Heinz-Josef Lenz ◽  
Neal J. Meropol ◽  
James Posey ◽  
David P. Ryan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Objective Response ◽  
Pancreatic Neuroendocrine Tumor ◽  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Tumor Patients ◽  
Patient Reported

Purpose Standard cytotoxic chemotherapy has limited efficacy in metastatic neuroendocrine tumor patients. Neuroendocrine tumors express vascular endothelial growth factor (VEGF) and its receptor (VEGFR). Sunitinib malate, an oral tyrosine kinase inhibitor, has activity against VEGFRs as well as platelet-derived growth factor receptors, stem-cell factor receptor, glial cell line–derived neurotrophic factor, and FMS-like tyrosine kinase-3. We evaluated the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neuroendocrine tumor patients. Patients and Methods Patients were treated with repeated 6-week cycles of oral sunitinib (50 mg/d for 4 weeks, followed by 2 weeks off treatment). Patients were observed for response, survival, and adverse events. Patient-reported outcomes were assessed. Results Among 109 enrolled patients, 107 received sunitinib (carcinoid, n = 41; pancreatic endocrine tumor, n = 66). Overall objective response rate (ORR) in pancreatic endocrine tumor patients was 16.7% (11 of 66 patients), and 68% (45 of 66 patients) had stable disease (SD). Among carcinoid patients, ORR was 2.4% (one of 41 patients), and 83% (34 of 41 patients) had SD. Median time to tumor progression was 7.7 months in pancreatic neuroendocrine tumor patients and 10.2 months in carcinoid patients. One-year survival rate was 81.1% in pancreatic neuroendocrine tumor patients and 83.4% in carcinoid patients. No significant differences from baseline in patient-reported quality of life or fatigue were observed during treatment. Conclusion Sunitinib has antitumor activity in pancreatic neuroendocrine tumors; its activity against carcinoid tumors could not be definitively determined in this nonrandomized study. Randomized trials of sunitinib in patients with neuroendocrine tumors are warranted.

scholarly journals The Impact of Repeating Endosonography with Confocal Endomicroscopy for the Diagnosis of Cystic Neuroendocrine Tumor

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Iqra Haq ◽  
Somashekar G. Krishna ◽  
Bhaveshkumar Patel ◽  
Thavam Thambi-Pillai ◽  
Chencheng Xie ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Pancreatic Pseudocyst ◽  
Incidental Finding ◽  
Pancreatic Neuroendocrine Tumor ◽  
Needle Aspiration ◽  
Confocal Laser Endomicroscopy ◽  
Confocal Laser ◽  
The Impact

Cystic pancreatic neuroendocrine tumors represent around 13% of all neuroendocrine tumors (Hurtado-Pardo 2017). There has been an increase in the incidence of cases due to improvement in imaging modalities. This is a case of a 68-year-old male with the incidental finding of a pancreatic cyst on CT. Initial Endoscopic Ultrasound with Fine Needle Aspiration (EUS-FNA) showed sonographic and cytology features suggestive of a pancreatic pseudocyst. However the cyst persisted with no change in size after aspiration leading to a follow-up EUS- FNA, which was combined with needle based confocal laser endomicroscopy (nCLE). The nCLE features were consistent with a cystic pancreatic neuroendocrine tumor, which was later confirmed on histology after surgical resection.

scholarly journals Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group

HPB ◽  
2020 ◽  
Vol 22 (7) ◽  
pp. 1042-1050
Author(s):  
Paula Marincola Smith ◽  
Jordan Baechle ◽  
Carmen C. Solórzano ◽  
Marcus Tan ◽  
Alexandra G. Lopez-Aguiar ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Study Group ◽  
Tumor Patients ◽  
The Us ◽  
Perioperative Blood Transfusion

Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

2016 ◽  
Vol 12 (10) ◽  
pp. 1251-1260 ◽  
Author(s):  
Sara Pusceddu ◽  
Roberto Buzzoni ◽  
Claudio Vernieri ◽  
Laura Concas ◽  
Sara Marceglia ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients ◽  
Patients With Diabetes

scholarly journals Proporsi Vanillylmandelic Acid Urin pada Pasien Terduga Tumor Neuroendokrin: Hubungannya dengan Usia dan Jenis Kelamin

2020 ◽  
Vol 9 (1) ◽  
pp. 27-34
Author(s):  
Annada Sofia ◽  
Mohamad Sadikin ◽  
Sri Widia Jusman ◽  
Septelia Inawati Wanandi ◽  
Ani Retno Prijanti ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Secondary Data ◽  
Spot Test ◽  
Vanillylmandelic Acid ◽  
Tumor Patients ◽  
Cross Sectional ◽  
Examination Result ◽  
Cross Sectional Design ◽  
And Gender

Abstract Cancer prevalence in Indonesia is 1.8 per 1000 population in 2018. Early diagnosis is needed to reduce the mortality rate and one of which is by examining vanillylmandelic acid (VMA) level as tumor markers. VMA is a catecholamine metabolite whose level will increase in several neuroendocrine tumors. This study was conducted to determine the proportion of positive VMA in urine of patients with suspected neuroendocrine tumors in Jakarta and its association with age and gender. This study was a cross-sectional design using secondary data of urinary VMA laboratory examination from 295 patients who suspected neuroendocrine tumors period 2010 to 2019 in Laboratory of Department of Biochemistry and Molecular Biology, Faculty of Medicine Universitas Indonesia. Qualitative examination of urinary VMA used spot test. Positive examination result showed levels of VMA in urine >8mg/24 hours, while negative result showed  8mg/24 hours. Inclusion criteria were subject data with a provisional diagnosis of neuroblastoma, pheochromocytoma, and paraganglioma. The proportion of positive VMA in urine of suspected neuroendocrine tumor patients was 14,2%. There was a significant association between VMA in urine with age (p 0,023), while gender was not significant (p 0,885). In conclusion, there was an association between urinary VMA of suspected neuroendocrine tumor patients with age, however no association with gender.   Keywords: neuroendocrine tumors; urinary vanillylmandelic acid; age; gender     Abstrak Prevalensi kanker di Indonesia pada 2018 adalah 1,8 per 1000 penduduk. Diagnosis dini dibutuhkan untuk mengurangi angka mortalitas, salah satunya melalui pemeriksaan penanda tumor berupa vanillylmandelic acid (VMA). VMA termasuk metabolit katekolamin yang meningkat produksinya pada beberapa tumor neuroendokrin. Penelitian dilakukan untuk mengetahui proporsi VMA positif dalam urin pasien dugaan tumor neuroendokrin di Jakarta serta hubungannya dengan usia dan jenis kelamin. Penelitian ini menggunakan desain cross-sectional yang menggunakan data sekunder hasil pemeriksaan laboratorium VMA urin dari 295 pasien dugaan tumor neuroendokrin periode 2010 hingga 2019 di Laboratorium Departemen Biokimia dan Biologi Molekuler, Fakultas Kedokteran Universitas Indonesia. Data VMA kualitatif yang diperoleh, diperiksa dengan metode spot test. Hasil positif menunjukkan kadarnya > 8 mg/24 jam, sedangkan hasil negatif menunjukkan kadarnya  8 mg/24 jam. Kriteria inklusi berupa diagnosis sementara neuroblastoma, pheochromocytoma, dan paraganglioma. Proporsi VMA positif dalam urin pasien dugaan tumor neuroendokrin adalah 14,2%. Terdapat hubungan bermakna antara kadar VMA dalam urin dengan usia (p 0,023), sedangkan dengan jenis kelamin menunjukkan hasil yang tidak bermakna (p 0,885). Dengan demikian dapat disimpukan bahwa terdapat hubungan antara VMA urin pasien dugaan tumor neuroendokrin dengan usia, namun tidak terdapat hubungan dengan jenis kelamin.   Kata kunci: tumor neuroendokrin; vanillylmandelic acid urin; usia; jenis kelamin  

ALCAM (CD166) Expression as Novel Prognostic Biomarker for Pancreatic Neuroendocrine Tumor Patients

2011 ◽  
Vol 170 (2) ◽  
pp. 226-232 ◽  
Author(s):  
Michael Tachezy ◽  
Hilke Zander ◽  
Andreas H. Marx ◽  
Florian Gebauer ◽  
Tamina Rawnaq ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Prognostic Biomarker ◽  
Pancreatic Neuroendocrine Tumor ◽  
Tumor Patients

scholarly journals Insulin-dependence predicts disease-specific survival in pancreatic neuroendocrine tumor patients

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S57
Author(s):  
J.J. Baechle ◽  
P.M. Smith ◽  
C.E. Bailey ◽  
A.G. Lopez-Aguiar ◽  
M. Dillhoff ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Disease Specific Survival ◽  
Tumor Patients ◽  
Insulin Dependence ◽  
Disease Specific
Sign in / Sign up

Export Citation Format

Share Document